GlassScriptPhysician profile
Julia Anisimova
NPI 1710208228
$1,233.85
in general payments reported to CMS, 2019-2025
14 companies · $628 in 2025
The $628 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.87 · 2022: $109 · 2023: $319 · 2024: $144 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $946 · Consulting Fee: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.40 |
| Consulting Fee | $145.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $309.22 | 2025 | Axonics, General - Erectile Dysfunction |
| Antares Pharma, INC. | $174.40 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Olympus America INC. | $136.38 | 2025 | Itind System |
| Procept Biorobotics Corporation | $107.89 | 2024 | Aquabeam System |
| Horizon Therapeutics Plc | $101.08 | 2023 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $77.27 | 2023-2024 | Jynarque |
| Janssen Biotech, INC. | $69.30 | 2025 | Rybrevant, Carvykti |
| Sumitomo Pharma America, INC. | $61.56 | 2025 | Gemtesa |
| Convatec INC. | $58.16 | 2022 | |
| Tolmar, INC. | $51.84 | 2025 | Jatenzo |
| Novartis Pharmaceuticals Corporation | $36.57 | 2023-2024 | |
| Medtronic, INC. | $18.00 | 2021 | |
| Novo Nordisk INC | $18.00 | 2023 | Ozempic, Rybelsus |
| Endo Pharmaceuticals INC. | $14.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Anisimova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.